DiaMedica Therapeutics Inc.

Ownership Transactions Reported by 19 Insiders

Symbol
DMAC on Nasdaq
Location
301 Carlson Parkway, Suite 210, Minneapolis, MN

Insiders trading volume in the past year

DiaMedica Therapeutics Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Thomas Von Koch 10%+ Owner $13.8M +$3M +27.7% Jun 28, 2024
Jan Stahlberg 10%+ Owner $13.1M +$3M +29.8% Jun 28, 2024
Richard Jacinto II 10%+ Owner $12.8M Jun 23, 2023
Randall Michael Giuffre Director $3.41M Jan 2, 2025
Richard D. Pilnik Director $2.32M Jan 2, 2025
David J. Wambeke Chief Business Officer $1.48M Jun 1, 2024
James T. Parsons Director $573K Jan 2, 2025
Charles Pauling Semba Director $348K Jan 2, 2025
Amy L. Burroughs Director $205K Jan 3, 2023
Dietrich John Pauls President and CEO, Director $192K Jun 1, 2024
Richard Kuntz Director $169K Jan 2, 2025
Harry W. Alcorn Jr SVP, Clinical Operations $123K Sep 15, 2021
Scott Kellen CFO and Secretary $90.4K Jun 1, 2024
Dominic R. Cundari Chief Commercial Officer $7.84K Jun 1, 2024
Tanya Lewis Director $0 Jun 1, 2024
Sydney A. Gilman VP, Regulatory Affairs Jul 28, 2021
Kirsten L. Gruis Chief Medical Officer Jun 1, 2023
Julie VanOrsdel Daves SVP Clinical Development Oper. Jun 1, 2023
Masuoka K. Lorianne Chief Medical Officer Jan 22, 2024

Recent Insider Transactions by Companies or Individuals for DiaMedica Therapeutics Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.